Use of lipid‐lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2‐year results from Getting to an imprOved Understanding of Low‐Density lipoprotein cholesterol and dyslipidemia management (GOULD)

BACKGROUND: Chronic kidney disease (CKD) is a known risk factor of atherosclerotic cardiovascular disease (ASCVD). Per the 2018 American Heart Association/American College of Cardiology cholesterol guidelines, high‐risk ASCVD patients with CKD and low‐density lipoprotein cholesterol (LDL‐C) levels ...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaik, Aleesha, Kosiborod, Mikhail, de Lemos, James A., Gao, Qi, Mues, Katherine E., Alam, Shushama, Bhatt, Deepak L., Cannon, Christopher P., Ballantyne, Christie M., Rosenson, Robert S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748744/
https://www.ncbi.nlm.nih.gov/pubmed/36124341
http://dx.doi.org/10.1002/clc.23923

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748744/
https://www.ncbi.nlm.nih.gov/pubmed/36124341
http://dx.doi.org/10.1002/clc.23923

Ejemplares similares